Retinal vessel loss indicates disability and grey matter atrophy in patients with relapsing remitting multiple sclerosis (2021) Romahn EF, Bussas M, Grahl S, Noll C, Wicklein R, Aly L, Berthele A, et al. Conference contribution Association of the retinal vasculature and intrathecal immunity during relapsing remitting multiple sclerosis (2021) Noll C, Aly L, Hiltensperger M, Wicklein R, Mitsdorffer M, Herrmann D, Gasperi C, et al. Conference contribution IMU-838, a small molecule DHODH inhibitor in phase II clinical trial for multiple sclerosis, shows potent Anti-EBV activity in cell-culture-based systems: Potential additional benefits in multiple sclerosis treatment (2021) Marschall M, Peelen E, Müller R, Wangen C, Wagner S, Muehler A, Groeppel M, et al. Conference contribution Autoimmune glomerulonephritis in a multiple sclerosis patient after cladribine treatment (2021) Schoenfelder K, Schuh H, Pfister F, Kraemer J, Eisenberger U, Skuljec J, Hackert J, et al. Journal article Validity of step detection in persons with MS: evaluation of activity trackers and a disease-specific algorithm using smartphone data (2020) Hartung V, Sarshar M, Shammas L, Rashid A, Roullier P, Maeurer M, Eilers C, et al. Conference contribution Attitudes towards physical activity and digital physical activity promotion in persons with Multiple Sclerosis (2020) Tallner A, Neumuller L, Pfeifer K Conference contribution Moving exercise research in multiple sclerosis forward (the MoXFo initiative): Developing consensus statements for research (2020) Dalgas U, Hvid LG, Kwakkel G, Motl RW, de Groot V, Feys P, Op’t Eijnde B, et al. Journal article Long-term disease stability assessed by the expanded disability status scale in patients treated with Cladribine tablets in the CLARITY and CLARITY extension studies (2019) Giovannoni G, Comi G, Rammohan K, Rieckmann P, Vermersch P, Dangond F, Keller B, Jack D Conference contribution Ecological validity of the two minute walk test in persons with multiple sclerosis (2019) Weiß V, Hartung V, Tallner A, Streber R, Wanner P, Shammas L, Rashid A, et al. Conference contribution Efficacy of Cladribine Tablets in high disease activity subgroups of patients with relapsing multiple sclerosis: A post hoc analysis of the CLARITY study (2019) Giovannoni G, Sorensen PS, Cook S, Rammohan KW, Rieckmann P, Comi G, Dangond F, et al. Journal article